Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.9352W HIGH $43.65
Volume
160.03 K
Value Traded
691.32 K
Short % Float
2.55%
-6.09%Week
-41.62%1 Month
-67.07%3 Month
-62.76%6 Month
-99.26%5 Year
-99.15%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
14.41 M
EPS (TTM)
-2.30
P/E Ratio
-
Ent. Value
-1.36 M
Total Shares
13.34 M
Float Shares
10.04 M
Insiders
24.71%
Institutions
16.72%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
TVRD Catalyst Timeline
Dated clinical, regulatory and corporate events for Tvardi Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Tvardi Therapeutics, Inc.
442Total events
10Upcoming
167Tier-1 (high impact)
2014 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Preclinical PoCTTI-101Preclinical
Preclinical data published in Int J Mol Sci showing TTI-101 prevented colon adenocarcinoma formation in chronic AOM-DSS model
ulcerative colitis-associated colorectal cancersource ↗
▲PublicationTTI-101Presentation
Publication in International Journal of Molecular Sciences of STAT3 inhibition preclinical study
ulcerative colitis-associated colorectal cancersource ↗
▲Topline ReadoutTTI-109Clinical Data
Reported topline healthy volunteer results for TTI-109
healthy volunteerssource ↗
▲Trial CompletionTTI-109Trial
Phase 1 healthy volunteer study of TTI-109 completed
healthy volunteerssource ↗
◆Topline ReadoutTTI-109Clinical Data
TTI-109 Phase 1 healthy volunteer topline data
healthy volunteersource ↗
◆Topline ReadoutTTI-101Clinical Data
HCC Phase 1b/2 topline data expected in 1H:2026
Hepatocellular Carcinomasource ↗
◆Topline ReadoutTTI-101Clinical Data
TTI-101 Phase 1b/2 HCC topline data
hepatocellular carcinoma (HCC)source ↗
◆Topline ReadoutTTI-109Clinical Data
Healthy volunteer study results for TTI-109
healthy volunteerssource ↗
◆Timing GuidancePresentation
Combined company expected to have cash runway into second half of 2026
◆Oral PresentationTTI-101Presentation
Podium presentation of Phase 2 REVERT IPF data at J.P. Morgan Healthcare Conference
idiopathic pulmonary fibrosissource ↗
▲Full ResultsTTI-101Clinical Data
New Phase 2 REVERT IPF data reported
idiopathic pulmonary fibrosissource ↗
◆Topline ReadoutTTI-109Clinical Data
Preliminary topline data from healthy volunteer study of TTI-109
healthy volunteersource ↗
◆Topline ReadoutTTI-101Clinical Data
Topline results from TTI-101 Phase 2 HCC trial expected 1H 2026
Hepatocellular carcinomasource ↗
◆Topline Readoutoral difelikefalinClinical Data
KOURAGE 1B & 2 topline results expected
notalgia parestheticasource ↗
◆Topline ReadoutdifelikefalinClinical Data
KOURAGE 1 Part B & KOURAGE 2 Phase 3 topline data in NP
notalgia parestheticasource ↗
◆Topline ReadoutTTI-101Clinical Data
Phase 2 unblinded data in IPF
Idiopathic Pulmonary Fibrosissource ↗
◆Topline ReadoutdifelikefalinClinical Data
Final topline results from first pivotal study (KOURAGE 1 Part B)
notalgia parestheticasource ↗
◆Topline ReadoutTTI-101Clinical Data
IPF Phase 2 unblinded data expected in 2H:2025
Idiopathic Pulmonary Fibrosissource ↗
▼Topline ReadoutTTI-101Clinical Data
Preliminary data from Phase 2 REVERT trial of TTI-101 in IPF
idiopathic pulmonary fibrosissource ↗
◆Topline ReadoutTTI-101Clinical Data
Topline data from REVERT IPF Phase 2 trial
idiopathic pulmonary fibrosis (IPF)source ↗
▲First Patient DosedTTI-109Trial
Healthy volunteer study of TTI-109 began in Q3 2025
healthy volunteersource ↗
◆Topline ReadoutTTI-101Clinical Data
Topline data from REVERT IPF Phase 2 trial
Idiopathic Pulmonary Fibrosissource ↗
▲Enrollment CompleteTTI-101Trial
Completed enrollment in Phase 2 REVERT IPF trial of TTI-101
idiopathic pulmonary fibrosissource ↗
◆Poster PresentationTTI-101Presentation
Abstract presentation at American Thoracic Society 2025 Annual Conference
Idiopathic Pulmonary Fibrosissource ↗
◆Full ResultsTTI-101Clinical Data
Phase 1 study results published in Clinical Cancer Research
Advanced Solid Tumorssource ↗
◆Topline ReadoutTTI-101Clinical Data
Topline data from Phase 2 trial of TTI-101 in IPF
idiopathic pulmonary fibrosis (IPF)source ↗
Past FDA Catalysts and PDUFA Decisions
How TVRD actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-08-19 | TTI-109 | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D27 / 100
Pipeline Score
$1M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.1x
rNPV / MCap
Top 78%
Micro Cap(rank 513 of 658)
Percentile Rank
Tvardi Therapeutics, Inc. faces pipeline headwinds (27/100), with $206M risk-adjusted pipeline value, led by TTI-101 in Breast Cancer (Phase 1), but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| TTI-101 Small moleculeCompletedNCT05671835 | Idiopathic Pulmonary Fibrosis | Phase 2 | COMPLETED | 100 | Aug 14, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every TVRD program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| TTI-109 | ulcerative colitis | Phase 1 | 2026-07-30 | up to 76% reduction in subsets associated with mucosal destruction and treatment-refractory UC; up to 43% in Tfh subsets associated with disease UC activity; up to 71% decline in subsets associated with colonic inflammationRead More | Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TVRD
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PARKMAN HEALTHCARE PARTNERS LLC | 0.3 % | 2.53 M | 65.00 K |
TVRD Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TVRD ranks across every disease it competes in
Competitive Position is a premium feature
See how TVRD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTVRD News
TVRD▼ -19.7%on this news
New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC)
Tvardi Therapeutics announced promising preclinical data for its STAT3 inhibitors, TTI-101 and TTI-109, in treating ulcerative colitis (UC). The studies demonstrated that TTI-101 achieves high concentrations in the colon, effectively normalizing disease-associated gene expression and preventing tumor formation. These findings support the potential of STAT3 inhibition as a therapeutic strategy for UC.
Read more →TVRDTvardi Therapeutics to Participate in Upcoming Investor Events
Tvardi Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in several upcoming investor events, including the Wells Fargo Healthcare Conference and the H.C. Wainwright Global Investment Conference. The company is focused on developing oral therapies targeting STAT3 for inflammatory diseases. Their lead candidate, TTI-109, has shown promising results in early studies.
Read more →TVRD▲ +7.3%on this news
Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update
Tvardi Therapeutics reported positive topline results for its STAT3 inhibitor TTI-109, confirming its prodrug design and improved tolerability. The company has selected ulcerative colitis as the initial indication and will host a webinar on its clinical potential. Despite a net loss of $6.5 million in Q2 2026, the company anticipates sufficient cash to fund operations through 2027.
Read more →TVRDTvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026
Tvardi Therapeutics will host a KOL webinar on August 19, 2026, featuring Dr. Randy Longman to discuss the treatment landscape for ulcerative colitis (UC) and the potential of TTI-109. The webinar will present new data from a Phase 1 study and outline the company's clinical development strategy. A live Q&A session will follow the presentations.
Read more →TVRDTvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109
Tvardi Therapeutics has selected ulcerative colitis as the initial indication for its STAT3 inhibitor, TTI-109, following a successful Phase 1 study. The drug demonstrated significant modulation of immune cell populations linked to UC pathology. A KOL webinar is planned to discuss the treatment landscape and TTI-109's potential. A clinical trial is expected to start in 2027, pending regulatory clearance.
Read more →TVRD▲ +54.2%on this news· ran to +149% by day 1
Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement
Tvardi Therapeutics announced positive Phase 1 results for TTI-109, a next-generation STAT3 inhibitor. The study confirmed TTI-109's rapid conversion to TTI-101, improved tolerability, and significant reductions in disease-relevant immune cell populations. The company plans to advance TTI-109 into dermatologic and gastrointestinal diseases, pending funding and regulatory approvals.
Read more →TVRDTvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update
Tvardi Therapeutics reported its Q1 2026 financial results, highlighting progress in its clinical trials. The company anticipates topline data from its next-generation STAT3 inhibitor, TTI-109, in June 2026, and is on track for results from the Phase 2 trial of TTI-101 in hepatocellular carcinoma in the second half of 2026. Despite a net loss, Tvardi expects its cash runway to support operations through late 2026.
Read more →TVRDTvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium
Tvardi Therapeutics, a clinical-stage biopharmaceutical company, will participate in one-on-one investor meetings at the Raymond James Biotech Innovation Symposium in New York City on April 14th, 2026. The company focuses on developing novel therapies targeting STAT3 for inflammatory and proliferative diseases. Their ongoing clinical trials include TTI-101 for hepatocellular carcinoma and TTI-109 in healthy volunteers.
Read more →TVRD▼ -5.7%on this newsshared move
Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update
Tvardi Therapeutics reported its fourth quarter and full-year 2025 results, highlighting key upcoming clinical milestones for its STAT3 inhibitors TTI-109 and TTI-101. The company anticipates topline data from a Phase 2 trial in hepatocellular carcinoma in H2 2026 and has sufficient cash to fund operations through Q4 2026. Despite a reduction in net loss, operational expenses have increased due to merger-related costs.
Read more →TVRDTvardi Therapeutics to Participate in Upcoming Investor Conferences
Tvardi Therapeutics, a clinical-stage biopharmaceutical company, has announced its participation in several upcoming investor conferences. These include the JonesTrading C-Suite Fireside Chat, Oppenheimer Healthcare Conference, TD Cowen Health Care Conference, and Barclays Global Healthcare Conference. The company aims to showcase its novel therapies targeting STAT3 for fibrosis-driven diseases.
Read more →TVRDOverview January 2026 This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, inc
Tvardi Therapeutics has highlighted its upcoming clinical milestones, including the Phase 1 trial results for TTI-109 and topline results for TTI-101 in hepatocellular carcinoma (HCC). The company emphasizes the potential of its investigational therapies targeting STAT3 to offer disease-modifying effects. While encouraging preliminary data have been noted, the company acknowledges the inherent risks and uncertainties in clinical research, particularly in cross-study comparisons. Results from various ongoing trials are anticipated in 1H 2026, with a focus on enhancing treatment options in fibrosis-driven diseases.
Read more →TVRD▲ +7.6%on this news
Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Tvardi Therapeutics will present new data from its Phase 2 REVERT IPF clinical trial at the 44th Annual J.P. Morgan Healthcare Conference. The data shows encouraging results regarding TTI-101's effects on fibrosis and pulmonary function. The presentation is scheduled for January 15, 2026, in San Francisco, CA.
Read more →TVRD▲ +8.7%on this newsshared move
Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights
Tvardi Therapeutics has reported further findings from its Phase 2 REVERT IPF trial of TTI-101 for idiopathic pulmonary fibrosis (IPF). The data indicate a 9.4% reduction in fibrosis scores among TTI-101 patients versus a 2.4% decline in the placebo group. Additionally, 63% of patients treated with TTI-101 showed improvements in lung function, specifically forced vital capacity (FVC), compared to 46% in the placebo group. Despite some positive indicators, the trial did not initially meet all its stated goals. Tvardi is also progressing with a Phase 1 study on TTI-109, a next-generation STAT3 inhibitor, projected to provide further insights in 2026.
Read more →TVRDOverview November 2025 This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, in
Tvardi Therapeutics, ticker TVRD, is conducting pioneering research focused on the inhibition of STAT3 for treating fibrotic diseases and hepatocellular carcinoma. The company reported a strong financial position with $36.5 million in cash, sufficient to fund operations through the end of 2026. Upcoming clinical milestones in 2026 include results from the TTI-109 Phase 1 trial and TTI-101's Phase 2 trial in HCC. Positive animal model data suggests that TTI-101 may effectively modulate immune responses and reduce fibrosis, positioning it as a promising candidate in the biopharma space.
Read more →TVRDTvardi Therapeutics Announces Third Quarter 2025 Results
Tvardi Therapeutics has announced its financial results for the third quarter of 2025 and provided an update on its clinical activities. The company is awaiting topline data from its Phase 2 trial of TTI-101 in hepatocellular carcinoma set for H1 2026, while also advancing its next-generation inhibitor TTI-109. Despite a net loss of $5.5 million, Tvardi's current cash resources are expected to fund operations through Q4 2026. The firm expresses confidence in the therapeutic potential of its products amid ongoing trials and operational adjustments.
Read more →TVRD▼ -83.9%on this news
Tvardi Therapeutics Provides Update on Preliminary Data from 2 REVERT Trial in Idiopathic Pulmonary Fibrosis
Tvardi Therapeutics has released preliminary results from its Phase 2 REVERT trial for TTI-101 in patients with idiopathic pulmonary fibrosis (IPF). The trial did not meet its primary objectives, showing no significant efficacy compared to placebo, despite the treatment arms having comparable baseline characteristics. Notably, there were higher rates of discontinuation due to gastrointestinal adverse events in the treatment groups. Tvardi plans to conduct further analyses to understand these results and inform future steps.
Read more →TVRDTvardi Therapeutics Announces Second Quarter 2025 Results and Provides Business Update
Tvardi Therapeutics reported its financial results for the second quarter of 2025, highlighting significant advancements in its clinical trials. The company is preparing for topline data from its Phase 2 REVERT IPF trial, expected in Q4 2025. Additionally, interim data from another trial indicated meaningful activity for its lead product, TTI-101, in treating liver cancer. The company also stated that its current cash runway is sufficient to fund its operations into Q4 2026.
Read more →TVRD▼ -5.6%on this news
Overview June 2025 This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, includ
The presentation discusses the forward-looking prospects of TTI-101, an investigational drug targeting STAT3 in fibrotic diseases, including idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC). Initial data suggest TTI-101 may effectively reverse fibrosis and restore lung function in IPF. The drug also demonstrates promising results in HCC, showing encouraging trends in monotherapy and in combination treatments. Key data catalysts are expected soon, including Phase 2 unblinded results in 2025 and topline results for HCC trials in 2026.
Read more →About Tvardi Therapeutics, Inc.
Headquarters3 SUGAR CREEK CTR. BLVD., SUGAR LAND, TX, 77478
BIOPHARMAWATCH ELITE PLUS
Trade the next TVRD catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime